- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07798011
Precision TOF-Guided Sugammadex Versus Spontaneous Recovery for Early Extubation in Minimally Invasive Pediatric Cardiac Surgery (TOF)
Precision Neuromuscular Management: Quantitative TOF-Guided Sugammadex Versus Spontaneous Recovery for Early Extubation in Pediatric Minimally Invasive Cardiac Surgery (A Prospective Observational Cohort Study)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
At the investigator's center, minimally invasive cardiac surgery (MICS) via a right mid-axillary approach for congenital heart defects such as ventricular septal defect (VSD) and atrial septal defect (ASD) accounts for approximately one-third of all pediatric cardiac surgeries requiring cardiopulmonary bypass (about 400 of 1,200 annual cases). In this high-volume setting, limited intensive care unit (ICU) bed availability creates a strong clinical imperative to facilitate early tracheal extubation, reduce mechanical ventilation duration, and shorten ICU length of stay.
Early extubation, including extubation in the operating room (OR), requires adequate recovery of consciousness, spontaneous ventilation, and analgesia. Advances in anesthetic management, including rapidly cleared sedatives, multimodal analgesia, and regional anesthesia techniques, have substantially reduced the impact of sedation and opioid-related respiratory depression. Consequently, residual neuromuscular blockade has become a major physiological barrier to successful early extubation.
In many pediatric cardiac centers in Vietnam, patients undergoing MICS are routinely transferred to the ICU with postoperative mechanical ventilation and without pharmacologic neuromuscular reversal. Even when surgical repair is uncomplicated and hemodynamics are stable, extubation is often delayed until spontaneous recovery from neuromuscular blockade occurs.
Sugammadex provides rapid and effective reversal of rocuronium-induced neuromuscular blockade and has an established safety profile. However, resource constraints may limit routine use, and evidence supporting precision dosing strategies in pediatric MICS remains limited. Quantitative train-of-four (TOF) monitoring serves as the foundation of the institution's neuromuscular management strategy by objectively measuring the depth and recovery of neuromuscular blockade, enabling informed decisions regarding either targeted sugammadex administration or continued observation for spontaneous recovery. This precision-monitoring approach may facilitate earlier extubation while avoiding unnecessary reversal therapy and associated costs.
This study is strictly observational. All patients receive standard care according to the institution's established early-extubation cardiac anesthesia pathway, which includes multimodal analgesia, processed electroencephalographic monitoring (SedLine/Patient State Index), and continuous quantitative TOF monitoring. The study does not alter perioperative management or influence the attending anesthesiologist's decision regarding neuromuscular reversal. Instead, it prospectively evaluates the clinical and resource outcomes associated with existing practice patterns.
The investigators hypothesize that quantitative TOF-guided neuromuscular management will be associated with higher rates of successful early operating room extubation, shorter mechanical ventilation duration, reduced ICU resource utilization, and safe avoidance of unnecessary sugammadex administration in selected patients.
Therefore, this prospective observational cohort study aims to:
- Compare neuromuscular recovery, resource utilization, and adverse events between quantitative TOF-guided sugammadex administration and monitored spontaneous recovery.
- Identify factors associated with successful early tracheal extubation following pediatric minimally invasive cardiac surgery.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Nguyen Thi Thu Hang, Medical Doctor
- Número de teléfono: +84 96 215 82 85
- Correo electrónico: hang.nguyen@nch.gov.vn
Copia de seguridad de contactos de estudio
- Nombre: Hung Nguyen, Professor
- Número de teléfono: 408-315-9801
- Correo electrónico: hung.nguyen@ucsf.edu
Ubicaciones de estudio
-
-
-
Hanoi, Vietnam, 100000
- Reclutamiento
- Vietnam National Children's Hospital (VNCH)
-
Contacto:
- Nguyen Hang, Medical Doctor
- Número de teléfono: +84 96 215 82 85
- Correo electrónico: hang.nguyen@nch.gov.vn
-
Contacto:
- Ba Tuan Nguyen, Medical Doctor, PhD
- Correo electrónico: Nguyenbatuan@hmu.edu.vn
-
Investigador principal:
- Truong Ly Thinh Nguyen, A/Professor
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
The study population consists of pediatric patients, aged 2 to 18 years, diagnosed with simple congenital heart defects (primarily Atrial Septal Defects and Ventricular Septal Defects). These patients are scheduled to undergo elective, minimally invasive cardiac surgery (MICS) utilizing cardiopulmonary bypass via a right mid-axillary thoracotomy approach.
To be included in the cohort, patients must be deemed appropriate clinical candidates for the institution's established early-extubation (fast-track) cardiac anesthesia pathway, which mandates the routine use of objective anesthetic depth monitoring (e.g., SedLine/Patient State Index) and continuous quantitative train-of-four (TOF) neuromuscular monitoring. Patients arriving intubated, requiring complex open sternotomy, or presenting with preexisting neuromuscular, hepatic, or renal disease that alters the pharmacokinetics of neuromuscular blocking agents are excluded from the population.
Descripción
Inclusion Criteria:
- Age older than 2 years and up to 18 years at the time of surgery.
- Scheduled for elective minimally invasive cardiac surgery (MICS) via a right mid-axillary thoracotomy for the repair of simple congenital heart defects (e.g., Ventricular Septal Defect, Atrial Septal Defect).
- Surgery requiring the use of cardiopulmonary bypass (CPB).
- Deemed an appropriate clinical candidate for the institutional early-extubation (fast-track) pathway.
- Intraoperative neuromuscular blockade maintained using rocuronium.
- Continuous intraoperative quantitative train-of-four (TOF) monitoring applied and calibrated.
- Written informed consent provided by a parent or legal guardian
Exclusion Criteria:
- Patients arriving at the operating room already intubated or requiring preoperative mechanical ventilation.
- Documented history of preexisting neuromuscular disorders (e.g., myasthenia gravis, muscular dystrophy) that alter the pharmacodynamics of neuromuscular blocking agents.
- Known hypersensitivity or severe allergic reaction to sugammadex, rocuronium, or any of their excipients.
- Severe preoperative hepatic dysfunction or renal impairment (e.g., estimated Glomerular Filtration Rate < [30] mL/min/1.73m²), which alters the clearance of sugammadex or muscle relaxants.
- Intraoperative surgical complications requiring conversion from a right mid-axillary thoracotomy to an open median sternotomy.
- Intraoperative events mandating delayed extubation for patient safety (e.g., severe hemodynamic instability, massive hemorrhage, or refractory arrhythmias).
- Inability to establish or maintain reliable quantitative TOF monitoring data during the procedure.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
TOF-Guided Sugammadex Cohort
Pediatric MICS patients whose attending anesthesiologist elected to administer sugammadex for NMB reversal, with the dose tailored to the precise depth of the neuromuscular block as measured by quantitative TOF monitoring.
|
Intravenous administration of sugammadex, with dosing (mg/kg) titrated to real-time quantitative train-of-four (TOF) monitoring data rather than standard fixed-weight dosing.
(Assigned to Cohort 1).
|
|
Monitored Spontaneous Recovery Cohort
Pediatric MICS patients whose attending anesthesiologist elected to forego pharmacological NMB reversal based on quantitative TOF monitoring, allowing the patient to achieve extubation criteria through actively monitored spontaneous recovery.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to Tracheal Extubation
Periodo de tiempo: Up to 24 hours post-surgery.
|
Time interval from the cessation of anesthetic maintenance agents (end of surgery) to successful tracheal extubation meeting predefined clinical criteria.
|
Up to 24 hours post-surgery.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to TOF Ratio >/= 0.90
Periodo de tiempo: Perioperative/Periprocedural
|
Time interval from the intervention (administration of sugammadex or start of spontaneous recovery observation) until the quantitative monitor displays a TOF ratio of >/= 0.90.
|
Perioperative/Periprocedural
|
|
Administered Sugammadex Dose
Periodo de tiempo: Intraoperative (at the time of NMB reversal).
|
The precise dose of sugammadex administered, calculated in mg/kg, based on the TOF-guided clinical decision.
|
Intraoperative (at the time of NMB reversal).
|
|
Specific Drug Cost Reductions
Periodo de tiempo: From enrollment to hospital discharge in 10 days
|
Calculated difference in drug acquisition costs between the tailored dose administered (or omitted in the spontaneous cohort) versus the standard theoretical 2.0 or 4.0 mg/kg dose.
|
From enrollment to hospital discharge in 10 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Nguyen Huu Tu, Professor, Hanoi Medical University (HMU)
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades cardiovasculares
- Enfermedades cardíacas
- Anomalías congénitas
- Anomalías cardiovasculares
- Defectos Cardíacos Congénitos
- Defectos del tabique cardíaco
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Defectos del tabique cardíaco, auricular
- Carbohidratos
- Compuestos policíclicos
- Polisacáridos
- Compuestos macrocíclicos
- gamma-ciclodextrinas
- Ciclodextrinas
- Dextrinas
- Almidón
- Glucanos
- Sugammadex
Otros números de identificación del estudio
- 6524/QĐ-ĐHYHN
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Marco de tiempo para compartir IPD
Criterios de acceso compartido de IPD
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .